论文部分内容阅读
目的 测定血浆中透明质酸 (HA)与尿毒症和肾移植患者病情变化的关系。方法 采用竞争性酶联免疫吸附试验测定尿毒症组 (A组 )、肾移植组 (B组 )、正常对照组 (C组 )血浆HA水平 ,同时测定血清肌酐 (SCr)。结果 血清HA水平A组 ( 414 2 5± 2 0 8 6 5ng/ml)高于B组 [( 6 9 5 7±46 2 8)ng/ml]和C组 [( 6 0 85± 2 5 5 5 )ng/ml](P <0 0 5 ) ;B组和C组比较差异无显著意义 (P >0 0 5 ) ,与血肌酐呈正相关 (r=0 87)。同时A组患者血肌酐透析前后比较差异有显著意义 [分别是透前 ( 810 48± 2 14 72 ) μmol/L透后 ( 2 2 5 2 8± 16 6 32 ) μmol/L ,(P <0 0 5 ) ];而血浆HA透析前后无变化[分别是透前 ( 414 2 5± 15 7 83)ng/ml]透后 ( 40 2 34± 12 5 6 7)ng/ml,(P >0 0 5 ) ]。结论 血HA可作为评估尿毒症和肾移植患者病情变化的一个指标。
Objective To determine the relationship between plasma hyaluronic acid (HA) and uremia and renal transplant patients. Methods The level of plasma HA in uremia group (A group), kidney transplantation group (B group) and normal control group (C group) were measured by competitive enzyme-linked immunosorbent assay. Serum creatinine (SCr) was also measured. Results Serum HA level was significantly higher in group A than in group B (414 2 5 ± 2 0 8 6 5 ng / ml) [(6 9 57 ± 46 2 8) ng / ml] and group C [(6 0 85 ± 2 5 5 5) ng / ml] (P <0.05). There was no significant difference between group B and group C (P> 0.05), and was positively correlated with serum creatinine (r = 0 87). At the same time, the difference of serum creatinine in group A before and after dialysis was significant (810 48 ± 2 14 72 μmol / L and 2 528 ± 16 6 32 μmol / L, P 0 (40 2 34 ± 125 6 7) ng / ml, P 0 (P0.05), but there was no change before and after plasma HA dialysis (414 2 5 ± 15 7 83 ng / ml) 0 5)]. Conclusion Blood HA can be used as an index to evaluate the changes of uremia and renal transplant patients.